Director of $PGEN sells 1,403,360 shares in insider sale

A recent insider sale of 1,403,360 shares of $PGEN by director Randal J Kirk caught the attention of investors. The transaction, which took place on 09-18-2025, amounted to an estimated $5,416,969. This sale represented approximately 10.4% of Kirk’s shares in the company, leaving him with 12,117,429 shares of $PGEN stock.

Insider trading activity for $PGEN has been relatively active in the past 6 months, with insiders making a total of 5 trades. Of these transactions, 3 were purchases and 2 were sales. In addition to Kirk’s recent sale, Nancy H Agee made 3 purchases of 41,005 shares, totaling an estimated $167,642.

Turning to hedge fund activity, 70 institutional investors have added shares of $PGEN to their portfolios, while 55 decreased their positions in the most recent quarter. Notable moves include Parkman Healthcare Partners LLC removing 1,648,520 shares, Schonfeld Strategic Advisors LLC removing 1,355,786 shares, and Patient Capital Management, LLC removing 1,103,560 shares. Conversely, Morgan Stanley added 1,007,864 shares, Susquehanna International Group, LLP added 975,244 shares, and Bank of America Corp/de/ added 599,914 shares to their respective portfolios.

Analysis from Wall Street analysts has been positive for $PGEN, with 3 firms issuing buy ratings on the stock. Notable recent ratings include a “Market Outperform” rating from JMP Securities, a “Buy” rating from HC Wainwright & Co, and an “Overweight” rating from Cantor Fitzgerald.

Multiple analysts have also provided price targets for $PGEN in the last 6 months, with a median target of $8.0. Analysts like Swayampakula Ramakanth from HC Wainwright & Co and Jason N. Butler from JMP Securities have set targets of $8.5 and $8.0, respectively.

In summary, recent insider trading, hedge fund activity, analyst ratings, and price targets indicate a level of interest and activity surrounding $PGEN. Investors may find these insights valuable when considering investment decisions, but it is essential to conduct thorough research and consult with financial advisors before making any investment choices.